Clinical Outcomes of Pregnant Individuals With Epilepsy - Prospective Study
Obstetrical & Neurological Outcomes in Individuals With Epilepsy During Pregnancy
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Esther Bui, MD
- Phone Number: 416-603-5320
- Email: Esther.Bui@uhn.ca
Study Contact Backup
- Name: Sharon Ng, BA
- Phone Number: 416-603-5320
- Email: Sharon.Ng@uhnresearch.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Recruiting
- University Health Network
-
Contact:
- Esther Bui, MD
- Phone Number: 416-603-5320
- Email: Esther.Bui@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- WWE seen at the Toronto Western Hospital Epilepsy Clinic since June 1st 2022.
- Pregnant at any point between June 1st 2022 and June 1st 2024 (period of enrolment).
- Diagnosed with epilepsy as per the International League Against Epilepsy (ILAE) 2014 definition of epilepsy.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of adherence to the 2015 Ontario Task Force management of epilepsy in pregnancy
Time Frame: 2 years
|
Describe the frequency of adherence to the 2015 Ontario Task Force management of epilepsy in pregnancy (i.e., AED regimen of WWE, frequency of polytherapy, adherence to serum monitoring of lamotrigine, and folic acid supplementation) and its association with year of pregnancy and type of healthcare provider.
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical (neurological, obstetrical, neonatal) outcomes during pregnancy
Time Frame: 1 year
|
To determine the association between adherence with the aforementioned guidelines and pregnancy, delivery, neonatal, and neurological outcomes when adjusting for baseline possible confounders.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-5753.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.